



Sigilon Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

September 2, 2021

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in two upcoming healthcare investor conferences.

Presentation Details:

Event: Morgan Stanley 19th Annual Global Healthcare Conference

Date: Friday, September 10, 2021

Time: 8:00 AM ET

Details: Live Fireside Chat

Event: H.C. Wainwright 23rd Annual Global Investment Conference

Date: Monday, September 13, 2021

Time: 7:00 AM ET

Details: On Demand Corporate Presentation

Webcasts of the Morgan Stanley fireside chat and the H.C. Wainwright corporate presentation will be accessible under "Events and Presentations" in the Investors & Media page of the Company's website at www.sigilon.com. A replay of each webcast will be available at the same location following the event.

About Sigilon Therapeutics

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon's product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon's Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor Contact

Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837

Media Contacts

Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349

Brandon Hagen
Manager, Communications
Sigilon Therapeutics
brandon.hagen@sigilon.com
617-586-2851